Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that ...

Compass Pathways plc , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the TD Cowen 45th ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...

Success of the operation with €42.9 million raised. Participation of US and European Healthcare specialist investors, as well as historical shareholders, in the transaction. Funds raised will ...

Other factors he attributed for the lower profit guidance included the immediate hit this year to Teva’s schizophrenia drug, Uzedy, from the Medicare Part D redesign under the Inflation Reduction Act; ...

UZEDY ®, the other drug, was approved by the US FDA in April 2023. Medincell’s partner Teva leads the clinical development and regulatory process and is responsible for commercialization of the ...

and Uzedy (risperidone) for treatment of schizophrenia. The three drugs collectively generated over $1.6 billion globally in 2023, or about 10.5% of Teva’s total sales, but we expect this number ...